Hence, current data bolster the notion that PL-metabolizing enzymes, particularly PNPLA3, may be involved in NAFLD development and thus may be used as targets for development of drugs for NAFLD/NASH treatment and prevention. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.